IKNA
Price:
$1.595
Market Cap:
$76.97M
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts...[Read more]
Industry
Biotechnology
IPO Date
2021-03-26
Stock Exchange
NASDAQ
Ticker
IKNA
According to Ikena Oncology, Inc.’s latest financial reports and current stock price. The company's current ROE is -39.59%. This represents a change of 304.90% compared to the average of -9.78% of the last 4 quarters.
The mean historical ROE of Ikena Oncology, Inc. over the last ten years is 9.73%. The current -39.59% ROE has changed -506.69% with respect to the historical average. Over the past ten years (40 quarters), IKNA's ROE was at its highest in in the December 2020 quarter at 25.78%. The ROE was at its lowest in in the September 2020 quarter at -1695.37%.
Average
9.73%
Median
5.48%
Minimum
-45.33%
Maximum
89.15%
Discovering the peaks and valleys of Ikena Oncology, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 176.24%
Maximum Annual ROE = 89.15%
Minimum Annual Increase = -137.47%
Minimum Annual ROE = -45.33%
Year | ROE | Change |
---|---|---|
2023 | -40.16% | -11.42% |
2022 | -45.33% | 176.24% |
2021 | -16.41% | -137.47% |
2020 | 43.80% | 60.07% |
2019 | 27.36% | -69.31% |
The current ROE of Ikena Oncology, Inc. (IKNA) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-33.97%
5-year avg
-6.15%
10-year avg
9.73%
Ikena Oncology, Inc.’s ROE is greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Design Therapeutics, Inc. (-18.01%), greater than Xilio Therapeutics, Inc. (-214.74%), less than Eliem Therapeutics, Inc. (0%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Werewolf Therapeutics, Inc. (-58.83%), greater than Stoke Therapeutics, Inc. (-54.45%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Celcuity Inc. (-62.66%), greater than MediciNova, Inc. (-20.70%), greater than Rezolute, Inc. (-69.83%), greater than Aerovate Therapeutics, Inc. (-90.19%), greater than Decibel Therapeutics, Inc. (-56.38%), less than Foghorn Therapeutics Inc. (167.93%), greater than Shattuck Labs, Inc. (-61.92%), greater than Kymera Therapeutics, Inc. (-24.96%), greater than Nurix Therapeutics, Inc. (-63.39%),
Company | ROE | Market cap |
---|---|---|
-26.83% | $2.81B | |
-18.01% | $352.47M | |
-214.74% | $51.87M | |
0% | $342.68M | |
-62.68% | $433.13M | |
-58.83% | $68.63M | |
-54.45% | $601.18M | |
-184.40% | $36.57M | |
-62.66% | $461.73M | |
-20.70% | $100.54M | |
-69.83% | $255.24M | |
-90.19% | $74.35M | |
-56.38% | $123.37M | |
167.93% | $272.13M | |
-61.92% | $52.99M | |
-24.96% | $2.64B | |
-63.39% | $1.37B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ikena Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ikena Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Ikena Oncology, Inc.'s ROE?
How is the ROE calculated for Ikena Oncology, Inc. (IKNA)?
What is the highest ROE for Ikena Oncology, Inc. (IKNA)?
What is the 3-year average ROE for Ikena Oncology, Inc. (IKNA)?
What is the 5-year average ROE for Ikena Oncology, Inc. (IKNA)?
How does the current ROE for Ikena Oncology, Inc. (IKNA) compare to its historical average?